Therapeutic Response

ER negative, HER2-negative, PD-L1 (CPS) >= 10, and PR negative status confers therapeutic sensitivity to Carboplatin in combination with Gemcitabine and Pembrolizumab in patients with Invasive Breast Carcinoma.

Statements

Source and description

Keytruda (pembrolizumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple negative breast cancer (TNBC) whose tumors express PD-L1 (CPS >= 10), as determined by an FDA approved test. This indication is based on KEYNOTE-355 (NCT02819518), a multicenter, double-blind, randomized, placebo-controlled trial where patients received either paclitaxel and paclitaxel protein-bound, or gemcitabine and carboplatin.